206 related articles for article (PubMed ID: 33531809)
1. Clinical Features and Long-Term Outcomes of Anti-Leucine-Rich Glioma-Inactivated 1 Encephalitis: A Multi-Center Study.
Qiao S; Wu HK; Liu LL; Wang ML; Zhang RR; Han T; Liu XW
Neuropsychiatr Dis Treat; 2021; 17():203-212. PubMed ID: 33531809
[TBL] [Abstract][Full Text] [Related]
2. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis.
Huang X; Fan C; Gao L; Li L; Ye J; Shen H
J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327
[TBL] [Abstract][Full Text] [Related]
3. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study.
Muñoz-Lopetegi A; Guasp M; Prades L; Martínez-Hernández E; Rosa-Justícia M; Patricio V; Armangué T; Rami L; Borràs R; Castro-Fornieles J; Compte A; Gaig C; Santamaria J; Dalmau J;
Lancet Neurol; 2024 Mar; 23(3):256-266. PubMed ID: 38365378
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and outcomes of leucine-rich glioma-inactivated protein 1 and contactin protein-like 2 antibody-associated autoimmune encephalitis in a Chinese cohort.
Li HY; Qiao S; Cui CS; Feng F; Liu XW; Yang XD
J Clin Neurosci; 2022 Jul; 101():137-143. PubMed ID: 35597061
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.
Guo K; Liu X; Lin J; Gong X; Li A; Liu Y; Zhou D; Hong Z
Ther Adv Neurol Disord; 2022; 15():17562864211073203. PubMed ID: 35069805
[TBL] [Abstract][Full Text] [Related]
6. Anti-LGI1 encephalitis with initiating symptom of seizures in children.
Wang Y; Zhang D; Tong L; Yang L; Yin P; Li J; Lei G; Yang X; Li B
Front Neurosci; 2023; 17():1151430. PubMed ID: 37179544
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics of Cognitive Impairment and 1-Year Outcome in Patients With Anti-LGI1 Antibody Encephalitis.
Hang HL; Zhang JH; Chen DW; Lu J; Shi JP
Front Neurol; 2020; 11():852. PubMed ID: 33162923
[No Abstract] [Full Text] [Related]
8. Mycophenolate mofetil reduces the risk of relapse in anti-leucine-rich glioma-inactivated protein 1 encephalitis: a prospective observational cohort study.
Liu M; Xu X; Fan S; Ren H; Zhao Y; Guan H
Neurol Sci; 2024 Jan; 45(1):253-260. PubMed ID: 37580515
[TBL] [Abstract][Full Text] [Related]
9. Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis.
Smith KM; Dubey D; Liebo GB; Flanagan EP; Britton JW
Neurology; 2021 Sep; 97(11):e1141-e1149. PubMed ID: 34233939
[TBL] [Abstract][Full Text] [Related]
10. [Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis].
Li JM; Ma XR; Peng T; Li JH; Lu H
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1947-1951. PubMed ID: 32629594
[No Abstract] [Full Text] [Related]
11. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABA
Shen CH; Fang GL; Yang F; Cai MT; Zheng Y; Fang W; Guo Y; Zhang YX; Ding MP
Ann Clin Transl Neurol; 2020 Aug; 7(8):1392-1399. PubMed ID: 32710704
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study.
Li W; Wu S; Meng Q; Zhang X; Guo Y; Cong L; Cong S; Zheng D
BMC Neurol; 2018 Jul; 18(1):96. PubMed ID: 29980179
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies.
Finke C; Prüss H; Heine J; Reuter S; Kopp UA; Wegner F; Then Bergh F; Koch S; Jansen O; Münte T; Deuschl G; Ruprecht K; Stöcker W; Wandinger KP; Paul F; Bartsch T
JAMA Neurol; 2017 Jan; 74(1):50-59. PubMed ID: 27893017
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Paroxysmal weakness of unilateral limb as an initial symptom in anti-LGI1 encephalitis: a report of five cases.
Wang S; Wang J; Li B; Hu N; Jin Y; Han S; Shang X
Front Immunol; 2023; 14():1191823. PubMed ID: 37304289
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA
de Bruijn MAAM; van Sonderen A; van Coevorden-Hameete MH; Bastiaansen AEM; Schreurs MWJ; Rouhl RPW; van Donselaar CA; Majoie MHJM; Neuteboom RF; Sillevis Smitt PAE; Thijs RD; Titulaer MJ
Neurology; 2019 May; 92(19):e2185-e2196. PubMed ID: 30979857
[TBL] [Abstract][Full Text] [Related]
16. Prolonged Corticosteroids Without Maintenance Immunotherapy for Treatment of Anti-LGI1 Encephalitis: Analysis of Outcomes and Relapse Rate.
Alkabie S; Budhram A
Neurol Neuroimmunol Neuroinflamm; 2023 May; 10(3):. PubMed ID: 37015827
[TBL] [Abstract][Full Text] [Related]
17. Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review.
Teng Y; Li T; Yang Z; Su M; Ni J; Wei M; Shi J; Tian J
Front Neurol; 2021; 12():791014. PubMed ID: 35095736
[No Abstract] [Full Text] [Related]
18. Clinical features of anti-leucine-rich glioma-inactivated 1 encephalitis in northeast China.
Zhao Q; Sun L; Zhao D; Chen Y; Li M; Lu Y; Li G; Lin W
Clin Neurol Neurosurg; 2021 Apr; 203():106542. PubMed ID: 33706063
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features and Gut Microbial Alterations in Anti-leucine-rich Glioma-Inactivated 1 Encephalitis-A Pilot Study.
Ma X; Ma L; Wang Z; Liu Y; Long L; Ma X; Chen H; Chen Z; Lin X; Si L; Chen X
Front Neurol; 2020; 11():585977. PubMed ID: 33193049
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Paroxysmal hyperhidrosis as an initial symptom in a patient with anti-LGI1 encephalitis.
Qiao T; Chen L; Jiang L; Wei H; Chen X; Li X; Chen Y; Xu Y
Front Immunol; 2022; 13():986853. PubMed ID: 36211373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
